Multiple Myeloma Clinical Trials in Newark, Delaware

4 studies are recruiting for multiple myeloma in Newark, Delaware right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

    The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).

    Stage
    Phase 3
    Ages
    18 and older
    Site
    ChristianaCare Helen F Graham Cancer Center and Research Institute, Newark, Delaware
    Locations
    270 in total
    Run by
    Janssen Research & Development, LLC

    See if you can join NCT05552222 on ClinicalTrials.gov

  2. A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

    Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Medical Oncology Hematology Consultants /ID# 268560, Newark, Delaware
    Locations
    46 in total
    Run by
    AbbVie

    See if you can join NCT05650632 on ClinicalTrials.gov

  3. Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

    This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Christiana Care, Newark, Delaware
    Locations
    212 in total
    Run by
    European Myeloma Network B.V.

    See if you can join NCT05243797 on ClinicalTrials.gov

  4. Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

    This is a phase II study to evaluate the outpatient administration of Teclistamab or Talquetamab in Multiple Myeloma patients

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Medical Oncology Hematology Consultants, Newark, Delaware
    Locations
    17 in total
    Run by
    SCRI Development Innovations, LLC

    See if you can join NCT05972135 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.